Clinical Trials Logo

Clinical Trial Summary

Nasal High Flow oxygen therapy (NHF) is commonly used as first line ventilatory support in patients with acute hypoxemic respiratory failure (AHRF). It's use has been initially limited in Covid-19 patients presenting with AHRF. The aim of the study is to describe the use of NHF in Covid-19-related AHRF and report the changes in the respiratory-oxygenation index (termed ROX index) over time in these patients.


Clinical Trial Description

Nasal High Flow oxygen therapy (NHF) is one of the newer methods of oxygenation commonly used in critical care during acute hypoxemic respiratory failure (AHRF). For various reasons (fear of a putative risk of viral dispersion; initial recommendations for rapid intubation due to the rapid deterioration of patients), NHF seems to have been seldomly used during the current Covid-19 epidemic in France. However, the World Health Organization, and other scientific societies list NHF among the possible options for ventilatory support.

One of the risks however, identified with NHF is to delay an intubation that would have become necessary. This delay seems to be associated with a poorer prognosis for patients.

The respiratory-oxygenation index (termed ROX index) (defined as the ratio of pulse oximetry (SpO2) over inspired fraction in oxygen (FiO2) over respiratory rate (RR); SpO2/FiO2/RR) is used - along with other criteria - to assist the clinician in deciding whether or not to intubate patients on NHF for AHRF. In investigators'ICU, NHF is used in patients admitted for AHRFrelated to Covid-19 and the ROX index is measured and monitoring in investigators' patients. Investigators' initial experience - consistent with feedback from other ICUs - suggests that the respiratory rate of patients with Covid-19-related AHRF is sometimes lower than would be expected given the depth of the hypoxemia. In this case, the ROX index thresholds previously identified for predicting the success or failure of NHF could be different in the case of Covid-19-associated AHRF. The purpose of this work is to describe the use of NHF in Covid-19 patients with AHRF and the evolution of the ROX score over time in patients initially treated with NHF. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04385823
Study type Observational
Source Hôpital Louis Mourier
Contact
Status Completed
Phase
Start date March 1, 2020
Completion date May 4, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Recruiting NCT04952337 - Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Not yet recruiting NCT05612893 - Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
Not yet recruiting NCT04397497 - Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Phase 2
Terminated NCT04345289 - Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia Phase 3
Enrolling by invitation NCT04326036 - Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection Early Phase 1
Withdrawn NCT00645619 - Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
Not yet recruiting NCT04876573 - Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 Phase 2
Unknown status NCT01612572 - A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals N/A
Completed NCT02152358 - PTH - Preemptive Treatment for Herpesviridae Phase 4
Completed NCT04644302 - Circulatory Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis
Recruiting NCT05531149 - Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04955223 - Yinhu Qingwen Granule in the Treatment of Viral Pneumonia Early Phase 1
Completed NCT01868113 - Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Phase 3
Recruiting NCT04380376 - Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia Phase 2
Completed NCT05386459 - Study of the Use of the Drug Ingaron in Patients With COVID-19
Not yet recruiting NCT06349707 - Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic
Completed NCT04394026 - Imaging Feature of SARS-CoV2 Infection
Not yet recruiting NCT04820751 - Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Phase 3